COMPASS Pathways plc (FRA:5Y6)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.48B +341.5% |
| Revenue (ttm) | n/a |
| Net Income | -166.84M |
| EPS | -2.67 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 11.40 |
| Previous Close | 11.70 |
| Day's Range | 11.40 - 11.60 |
| 52-Week Range | 2.10 - 12.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About COMPASS Pathways
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L... [Read more]
News
Why Trump Is Pushing Psychedelics To Treat Mental Illness
The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, marking a sharp reversal from his first term stance on drugs. Three compa...
Why Trump reversed course to fast-track psychedelic drugs for mental healthcare
President Donald Trump aims to fast-track research into psychedelic therapy for conditions like post traumatic stress disorder and depression in a break from his first administration policy. Advocates...
Compass Pathways Elects Kathleen Tregoning to Board of Directors
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways Transcript: RBC Capital Markets Global Healthcare Conference 2026
COMP360 psilocybin shows rapid, durable efficacy in treatment-resistant depression, with regulatory review and commercialization progressing swiftly. Infrastructure and site readiness are robust, and expansion into PTSD is supported by promising early data and VA collaboration.
Compass Pathways price target raised to $20 from $12 at Maxim
Maxim analyst Jason McCarthy raised the firm’s price target on Compass Pathways (CMPS) to $20 from $12 and keeps a Buy rating on the shares. Compass Pathways reported Q1 results…
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a treatment update and an analyst initiation. EARNINGS: On Thursday, GH…
Compass Pathways price target raised to $17 from $16 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Compass Pathways (CMPS) to $17 from $16 and keeps an Overweight rating on the shares.
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
COMPASS Pathways Earnings Call Transcript: Q1 2026
Positive phase III data for COMP360 in TRD supports a rolling NDA submission, with launch readiness targeted by year-end. Awarded a CNPV for accelerated FDA review, strong commercial and financial positioning, and advancing a late-stage PTSD program.
COMPASS Pathways Quarterly report: Q1 2026
COMPASS Pathways has published its Q1 2026 quarterly earnings report on May 13, 2026.
COMPASS Pathways Earnings release: Q1 2026
COMPASS Pathways released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
COMPASS Pathways Earnings release: Q1 2026
COMPASS Pathways released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Compass Pathways reports Q1 EPS (30c), consensus (31c)
Cash and cash equivalents were $466.0M as of March 31 compared with $149.6M as of December 31, 2025. Debt was $50.5M as of March 31 compared with $31.6M as of…
Compass Pathways expects cash position to fund the company into 2028
The company said, “The current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.”
COMPASS Pathways Slides: Investor presentation
COMPASS Pathways has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Psychedelic: Jefferies initiates Compass Pathways with a Buy rating
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an analyst initiation, patent filings and commercial manufacturing. COMPASS PATHWAYS I...
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal...
Compass Pathways initiated with a Buy at Jefferies
Jefferies initiated coverage of Compass Pathways (CMPS) with a Buy rating and $18 price target. The firm is 75%-85% confident the FDA will approve COMP360, the company’s oral psilocybin for…
Psychedelic: FDA awards Compass Pathways priority review voucher
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a BTD evaluation, granting of a priority review voucher and a collaboration…
COMPASS Pathways Transcript: Needham Virtual Psychedelics Forum
Psychedelic drug development is accelerating due to regulatory support, with multiple late-stage trials underway and companies preparing for commercial launches. Market differentiation will depend on efficacy, duration, and ease of use, while payer adoption and scalable infrastructure are key to broad access.
Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
Oppenheimer views FDA granting a CNPV with agreement on New Drug Application rolling review as reinforcing the firm’s conviction considering the earlier launch timeline for COMP360 in treatment-resist...
Compass Pathways announces FDA granted NDA rolling review request
Compass Pathways (CMPS) announced the U.S. Food and Drug Administration granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for t...